A single-center analysis of patients with extranodal marginal zone lymphoma of the breast. Issue 3 (23rd February 2022)

• Record Type: Journal Article
• Authors: Iyer, Sunil Girish; Kuker, Russ; Florindez, Jorge A.; Saul, Eduardo; Trabolsi, Asaad; Rodriguez, Gregor; Chapman, Jennifer R.; Lossos, Izidore S.; Alderuccio, Juan Pablo
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 3(2022)
• Page Start: 591
• Page End: 598
• Publication Date: 2022-02-23
• Subjects: Extranodal marginal zone lymphoma; breast lymphoma; treatment-related outcomes; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1992764
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Breast extranodal marginal zone lymphoma (EMZL) is a rare malignancy. We performed the largest published to date single-center retrospective analysis of 13 patients with breast EMZL focusing on clinical characteristics and treatment-related outcomes. The rarity of this disease at our center was concordant with the prevalence reported in the literature, with breast EMZL comprising 2% of 654 MZL cases. Most patients presented with stage I-II disease however four (30.8%) patients had stage IV disease mostly due to occult bone marrow (BM) involvement. Interestingly, EMZL was frequently non-FDG avid (66.7%) on staging PET/CT. With a median follow-up of 3.1 years (range 5 months to 10.2 years), the 3-year progression free survival was 68.7% (95%CI 30.2%–88.9%) and overall survival 80.2% (95%CI 40.3%-94.8%). No patient experienced higher-grade transformation. Herein we show that localized breast EMZL can be effectively treated with radiation therapy providing long term disease control.